An activating missense mutation of the MET gene and duplication of chromosome 7 along with the mutated MET gene were postulated to increase the oncogenic effect of MET [139, 140]. MET mutation associated hereditary pRCC and sporadic pRCC are typically low grade, bilateral tumours with multiple lesions [8, 9, 141]. This evidence concerns the gene MET and neoplasm.